← Human Trials & Peer-Reviewed Studies
Diamine oxidase (DAO) supplement reduces headache in episodic migraine patients with DAO deficiency: A randomized double-blind trial.
Plain-language guide to PMID 29475774 (2019): double-blind randomized controlled trial of Copper (Supplement) in 100 patients, migraine.
Key Facts
- PMID
- 29475774
- Journal
- Clinical nutrition (Edinburgh, Scotland)
- Year
- 2019
- Study type
- Randomized Controlled Trial
- Authors
- Izquierdo-Casas J et al. (7 authors)
- DOI
- 10.1016/j.clnu.2018.01.013
What This Study Did, in Plain Language
What Was Tested
Researchers studied Copper (Supplement) in the context of migraine in this randomized controlled trial publication.
Among histamine related symptoms, headache is one of the most recorded.
Current clinical strategies for the treatment of the symptomatology related to this disorder are based on the exclusion of foods with histamine or other bioactive amines and/or exogenous DAO supplementation.
Who Took Part
The abstract describes 100 patients taking part.
The age groups tagged for this paper are teenagers, young adults, adults and middle-aged adults, both men and women.
100 patients with confirmed episodic migraine according to current International Headache Society (IHS) criteria and DAO deficiency (levels below 80 HDU/ml) were randomized in two groups.
Clinical outcomes assessed were duration and number of attacks, perception of pain intensity and adverse effects during treatment.
How the Study Was Run
In design terms this was a randomized, double-blind and placebo-controlled study.
The patients were allocated by chance, so the Copper (Supplement) group and the comparison group should start out alike.
Blinding on both sides kept the patients and researchers unaware of who received Copper (Supplement).
Some patients received a placebo instead of Copper (Supplement), giving a reference point.
The use of triptans was also recorded.
What Was Measured
Topics PubMed links to this paper include Amine Oxidase (Copper-Containing), Dietary Supplements, Headache and Migraine Disorders.
The authors tagged it with the keywords DAO supplementation, Diamine oxidase (DAO), Histamine and Histamine intolerance.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement) in 100 patients in people with migraine.
Its findings take up roughly 10 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2019 (Clinical nutrition (Edinburgh, Scotland)), a journal based in England.
More context: the Copper (Supplement) compound page, Migraine research.
Our Notes on the Compound
Copper (Supplement): The active site of cytochrome c oxidase is described as containing copper ions that are essential for electron transfer.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.